{"disease":{"id":"pulmonary-embolism","name":"Pulmonary embolism","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":14,"pipeline_drug_count":0,"trial_count":18},"drugs":{"marketed":[{"drug_id":"edoxaban","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Savaysa","generic_name":"edoxaban","company_name":"Daiichi Sankyo Inc","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":73,"revenue":"1800","mechanism":"Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting."},{"drug_id":"dabigatran","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran etexilate","company_name":"Generic (originally Boehringer Ingelheim)","drug_phase":"marketed","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Direct oral anticoagulant (DOAC) — direct thrombin inhibitor","quality_score":69,"revenue":"1200","mechanism":"Direct thrombin inhibitor that blocks both free and clot-bound thrombin, providing anticoagulation without routine monitoring."},{"drug_id":"chembl-chembl48361","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"chembl-chembl48361","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran Etexilate","generic_name":"DABIGATRAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":65,"revenue":"1200","mechanism":"Dabigatran works by directly inhibiting the activity of thrombin, a key enzyme in the blood clotting process."},{"drug_id":"fondaparinux","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arixtra","generic_name":"FONDAPARINUX","company_name":"Mylan Ireland Ltd","drug_phase":"marketed","molecular_target":"Coagulation factor X","drug_class":"Factor Xa Inhibitor","quality_score":67,"revenue":null,"mechanism":"Arixtra works by blocking the action of factor Xa, a protein involved in blood clotting."},{"drug_id":"enoxaparin-sodium","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"heparin","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"heparin","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"rivaroxaban","indication_name":"Prevention of pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"rivaroxaban","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"dabigatran-etexilate","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pradaxa","generic_name":"dabigatran-etexilate","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Thrombin (serine protease)","drug_class":"Direct thrombin inhibitor","quality_score":71,"revenue":null,"mechanism":"Competitive direct thrombin inhibitor preventing fibrin formation and thrombus development."},{"drug_id":"heparin-sodium","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"heparin-sodium","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"acenocoumarol","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sintrom","generic_name":"ACENOCOUMAROL","company_name":"","drug_phase":"phase_3","molecular_target":"Vitamin K epoxide reductase complex subunit 1","drug_class":"acenocoumarol","quality_score":null,"revenue":null,"mechanism":"Acenocoumarol works by blocking the enzyme that helps produce clotting factors in the liver."},{"drug_id":"warfarin","indication_name":"Deep Vein Thrombosis with Pulmonary Embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Pulmonary Thromboembolism Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"warfarin","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coumadin","generic_name":"warfarin","company_name":"Generic (originally Wisconsin Alumni Research Foundation)","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7","drug_class":"Vitamin K antagonist (anticoagulant)","quality_score":60,"revenue":null,"mechanism":"Inhibits vitamin K epoxide reductase, blocking the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombosis."},{"drug_id":"alteplase","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Activase","generic_name":"ALTEPLASE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Plasminogen","drug_class":"","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"arixtra","indication_name":"Pulmonary thromboembolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Arixtra","company_name":"LifeBridge Health","drug_phase":"marketed","molecular_target":"Antithrombin-III, Coagulation factor X","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lovenox","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"activase","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Activase","company_name":"Medical College of Wisconsin","drug_phase":"discontinued","molecular_target":"Plasminogen","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"dabigatran-etexilate-de","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dabigatran etexilate (DE)","generic_name":"dabigatran-etexilate-de","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]","drug_class":"Dabigatran etexilate (DE) as oral capsule","quality_score":null,"revenue":null,"mechanism":"Dabigatran etexilate (DE) as oral capsule"},{"drug_id":"enoxaparin","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Prevention of pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xarelto","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"bemiparin","indication_name":"Pulmonary embolism","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"BEMIPARIN","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Factor Xa and thrombin (via antithrombin III enhancement)","drug_class":"Low Molecular Weight Heparin","quality_score":0,"revenue":null,"mechanism":"Fragmin works by binding to and activating antithrombin, which inhibits the coagulation cascade."}],"pipeline":[],"offLabel":[],"totalMarketed":28,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03660007","title":"Incidence of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer","phase":"","overall_status":"COMPLETED","enrollment_count":902891,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04969653","title":"The Incidence of Venous Thromboembolism in Atopic Dermatitis","phase":"","overall_status":"COMPLETED","enrollment_count":754745,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT01947959","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","phase":"","overall_status":"COMPLETED","enrollment_count":665533,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03271450","title":"The DARE Warfarin CER Study","phase":"","overall_status":"UNKNOWN","enrollment_count":416000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04838106","title":"Outcomes of Patients Who Survived Treatment on an Intensive Care Unit for COVID-19 in England and Wales","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":319600,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT01947985","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","phase":"","overall_status":"COMPLETED","enrollment_count":208958,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06232551","title":"Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":152000,"lead_sponsor_name":"Scott C. Woller, MD","has_results":false},{"nct_id":"NCT02468102","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04879407","title":"Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":98947,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT01947998","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","phase":"","overall_status":"COMPLETED","enrollment_count":50299,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05264168","title":"Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":41875,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04615065","title":"Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT07245927","title":"Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Supergene, LLC","has_results":false},{"nct_id":"NCT04574895","title":"Using a Real-Time Risk Prediction Model to Predict Pediatric Venous Thromboembolism (VTE) Events","phase":"NA","overall_status":"COMPLETED","enrollment_count":17427,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT02943343","title":"The China Pulmonary Thromboembolism Registry Study","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT04535128","title":"COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications","phase":"","overall_status":"COMPLETED","enrollment_count":11000,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT02155491","title":"Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events","phase":"","overall_status":"COMPLETED","enrollment_count":10679,"lead_sponsor_name":"Thrombosis Research Institute","has_results":false},{"nct_id":"NCT06581965","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":10078,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT04122573","title":"Prospective Multicenter Study for Early Evaluation of Acute Chest Pain","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06528418","title":"Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"ChromX Health","has_results":false},{"nct_id":"NCT06954727","title":"China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT04419194","title":"Effect of Climatic Factors on the Seasonal Fluctuation of Pulmonary Embolism","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT04400877","title":"Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic","phase":"","overall_status":"COMPLETED","enrollment_count":7795,"lead_sponsor_name":"University Hospital, Linkoeping","has_results":false},{"nct_id":"NCT02600260","title":"Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":7212,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT03034525","title":"Assessing the Risk of Pulmonary Embolism in Patients After Hospitalization for First Episode of Syncope","phase":"","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT03477968","title":"ThRombosis ExclUsion STudy","phase":"","overall_status":"TERMINATED","enrollment_count":5935,"lead_sponsor_name":"Diagnostica Stago","has_results":true},{"nct_id":"NCT04211181","title":"CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism","phase":"NA","overall_status":"RECRUITING","enrollment_count":5800,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT03631810","title":"Contemporary Clinical Management Of Acute Pulmonary Embolism","phase":"","overall_status":"COMPLETED","enrollment_count":5213,"lead_sponsor_name":"Heart Care Foundation","has_results":false},{"nct_id":"NCT03129555","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Herlev and Gentofte Hospital","has_results":false},{"nct_id":"NCT03881345","title":"Ongoing Registry of Treatment of Venous Thromboembolism","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Medalp Private Surgery Clinic","has_results":false},{"nct_id":"NCT05333042","title":"External Validation of a Deep Learning Based Model for Pulmonary Embolism Detection on Chest CT Scans","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"OncoRadiomics","has_results":false},{"nct_id":"NCT06341231","title":"Personalized Anticoagulant Therapy for Pulmonary Thromboembolism","phase":"","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT06320236","title":"Emergency Medicine Pulmonary Embolism Testing Multicentre Study","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Dr. Kerstin de Wit","has_results":false},{"nct_id":"NCT05723003","title":"Prospective Validation of an Acute Pulmonary Embolism Severity and Prognosis Prediction Model","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06093217","title":"Artificial Intelligence to Improve Detection and Risk Stratification of Acute Pulmonary Embolism (AID-PE)","phase":"","overall_status":"COMPLETED","enrollment_count":3872,"lead_sponsor_name":"Royal United Hospitals Bath NHS Foundation Trust","has_results":false},{"nct_id":"NCT05226416","title":"Analysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection","phase":"","overall_status":"COMPLETED","enrollment_count":3554,"lead_sponsor_name":"Eurasian Association of Therapists","has_results":false},{"nct_id":"NCT02064439","title":"Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3365,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT04158973","title":"CHIPs-VTE Study in Hospitalized Patients With Lung Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3200,"lead_sponsor_name":"China-Japan Friendship Hospital","has_results":false},{"nct_id":"NCT06015529","title":"Diagnostic Strategy for Suspected Pulmonary Embolism Based on 4PEPS","phase":"NA","overall_status":"COMPLETED","enrollment_count":3084,"lead_sponsor_name":"University Hospital, Angers","has_results":false},{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06382038","title":"Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2972,"lead_sponsor_name":"Navy General Hospital, Beijing","has_results":false},{"nct_id":"NCT06648837","title":"Microvisk Continuous Blood Donation Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Microvisk Technologies Ltd","has_results":false},{"nct_id":"NCT06183944","title":"Data Clustering Study With Artificial Intelligence and Phenotyping of Patients With Acute Pulmonary Embolism","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","has_results":false},{"nct_id":"NCT06258694","title":"Venous Thrombo-Embolism Imaging Database (VTE-ID)","phase":"","overall_status":"COMPLETED","enrollment_count":2208,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT02483442","title":"D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism","phase":"","overall_status":"COMPLETED","enrollment_count":2038,"lead_sponsor_name":"McMaster University","has_results":false},{"nct_id":"NCT03719027","title":"Prevalence of Chronic Thromboembolic Pulmonary Hypertension After Acute Pulmonary Embolism : (Preva-CTEPH)","phase":"NA","overall_status":"COMPLETED","enrollment_count":2003,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05482269","title":"Adverse Outcome of Acute Pulmonary Embolism by Artificial Intelligence System Based on CT Pulmonary Angiography","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT05481242","title":"An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT03657992","title":"Time Trend Analysis of PE Diagnosis With SPECT V/Q: a Single Institution Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Brest","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}